You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

 

Online download statistics by month:

Online download statistics by month: November 2020 to March 2026

AbstractFullPdf
Nov 2020208211178
Dec 202013513575
Jan 202111411457
Feb 202111211262
Mar 202115115138
Apr 2021747455
May 2021898948
Jun 2021797964
Jul 2021717155
Aug 2021737350
Sep 2021858562
Oct 202112512582
Nov 2021818183
Dec 2021828456
Jan 2022868944
Feb 2022788157
Mar 2022919372
Apr 202210210773
May 2022828261
Jun 2022939668
Jul 2022727438
Aug 2022878747
Sep 2022747650
Oct 2022929269
Nov 2022828242
Dec 2022535346
Jan 2023636345
Feb 202311111374
Mar 202310010076
Apr 202313213355
May 202313213242
Jun 202315015041
Jul 202311411542
Aug 202310811059
Sep 202310310335
Oct 202313113235
Nov 202319719733
Dec 2023177178136
Jan 2024127127128
Feb 202410510527
Mar 2024106106114
Apr 2024898932
May 202412112236
Jun 202413714336
Jul 202416216252
Aug 202414014241
Sep 202412712861
Oct 202411411437
Nov 202412512951
Dec 202410410653
Jan 2025586225
Feb 202511811943
Mar 202511211252
Apr 202510410550
May 2025808169
Jun 2025565642
Jul 2025220
Aug 2025110
Mar 2026110
Total597860343254